Boris Warnack came to Xeltis with a vast experience in the development, regulatory approval and commercialization of cardiovascular devices. Before joining Xeltis, he was senior program director at medical device company Biotronik, responsible for the development and global commercialization of their bioabsorbable drug-eluting stent. Prior to Biotronik, Warnack held various leadership positions in research, development and program management in Abbott Vascular and Jomed, and successfully brought a variety of cardiovascular devices to the market, including the first-of-its-kind fully bioabsorbable coronary stent ABSORB (Abbott). He started his career in the field of hemodialysis with Gambro and holds an MSc in engineering from the University of Kassel in Germany.
Regulatory development of devices to find the some infectious diseases